BeyondSpring, Inc.

Contributing Author

Recent Articles by BeyondSpring, Inc.

Jun-03	BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting BYSI GlobeNewswire
May-28	BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting BYSI GlobeNewswire
May-12	BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire